Celldex Therapeutics (CLDX) Asset Writedowns and Impairment (2017 - 2021)

Celldex Therapeutics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $3.5 million for Q3 2021.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $3.5 million in Q3 2021; TTM through Sep 2021 was $21.5 million, a N/A change from a year earlier, with the FY2021 full-year figure at $3.5 million, down 80.56% from the prior year.
• Asset Writedowns and Impairment fell to $3.5 million in Q3 2021 per CLDX's latest filing, from $14.5 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $14.5 million in Q4 2020 and bottomed at $1.8 million in Q1 2019.
• The 5-year median for Asset Writedowns and Impairment is $6.9 million (2018), against an average of $7.9 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 84.75% in 2019; the steepest drop was 84.75% in 2019.
• Year by year, Asset Writedowns and Impairment stood at $13.0 million in 2017, then plunged by 47.1% to $6.9 million in 2018, then sank by 73.83% to $1.8 million in 2019, then soared by 705.56% to $14.5 million in 2020, then tumbled by 75.86% to $3.5 million in 2021.
• Per Business Quant, the three latest CLDX Asset Writedowns and Impairment figures stand at $3.5 million (Q3 2021), $14.5 million (Q4 2020), and $3.5 million (Q2 2020).